Morgan Stanley analyst Thibault Boutherin raised the firm's price target on Novartis to $170 from $143 and keeps an Overweight rating on the shares. The firm came away from its deep dive into nine pipeline assets seeing $23B of risk-adjusted potential and an additional $13B upside in a 100% success scenario, the analyst tells investors. While the firm acknowledges risks, it believes that "the risk/reward remains to the upside, in particular on remibrutinib," the analyst added.
